FV100 as a new approach for the possible treatment of varicella-zoster virus infection

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 671-673

  McGuigan, Christopher ^a   Balzarini, Jan ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral; BCNA; Cf1743; Nucleoside; VZV

Indexed keywords

ANTIVIRUS AGENT; BICYCLIC NUCLEOSIDE DERIVATIVE; CF 1743; FV 100; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; EDITORIAL; HERPES ZOSTER; HUMAN; SINGLE DRUG DOSE; VARICELLA ZOSTER VIRUS;

ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; PYRIMIDINE NUCLEOSIDES;

EID: 70349445068     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp294     Document Type: Editorial

References (10)

1. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84.
2. Hope-Simpson R. The nature of herpes zoster: A long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9-20.
3. British National Formulary. September 2007; 54: 332-5.
4. Beutner KR, Friedman DJ, Forszpaniak C et al. Valaciclovir compared with acyclovir for improved therapy to herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39 1546-53.
5. McGuigan C, Barucki H, Blewett S et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 2000; 43: 4993-7.
6. McGuigan C, Pathirana RN, Migliore M et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother 2007; 60: 1316-30.
7. Sienaert R, Naesens L, Brancale A et al. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol 2002; 61: 249-54.
8. Balzarini J, Sienaert R, Liekens S et al. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol 2002; 61: 1140-5.
9. Balzarini J, McGuigan C. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim Biophys Acta 2002; 1587: 287-95.
10. Matson M, Pentikis H, Boehlecke B et al. A study of the safety and pharmacokinetics of multiple ascending doses of FV-100 in healthy subjects. Antiviral Res 2009; 82: A49.